AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice.
暂无分享,去创建一个
[1] N. Tewari-Singh,et al. Tumor Necrosis Factor-α Induces Endothelial Dysfunction in Leprdb Mice , 2007 .
[2] S. Yagihashi,et al. Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.
[3] L. Velloso,et al. Increased expression of advanced glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats , 2005, Diabetologia.
[4] M. Andrassy,et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.
[5] M. Focardi,et al. Tumor Necrosis Factor- (cid:1) Induces Endothelial Dysfunction in the Prediabetic Metabolic Syndrome , 2022 .
[6] Alan W. Stitt,et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. , 1997, The American journal of pathology.
[7] Lei Feng,et al. Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. , 2005, Diabetes care.
[8] P. Low,et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[9] Hiroshi Yamamoto,et al. The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[10] L. Kuo,et al. Myogenic activity in isolated subepicardial and subendocardial coronary arterioles. , 1988, The American journal of physiology.
[11] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[12] Merlin C. Thomas,et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.
[13] A. M. Lefer,et al. Cytokines and growth factors in endothelial dysfunction , 1993, Critical care medicine.
[14] L. Kuo,et al. TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[15] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[16] I. Boros,et al. The proteasome inhibitor MG132 protects against acute pancreatitis. , 2005, Free radical biology & medicine.
[17] A. Schmidt,et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. , 2006, Atherosclerosis.
[18] R. Furchgott,et al. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.
[19] S. Spiegel,et al. Sphingosine kinase functionally links elevated transmural pressure and increased reactive oxygen species formation in resistance arteries , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] L. Køber,et al. Tumor Necrosis Factor-&agr; Inhibits Insulin’s Stimulating Effect on Glucose Uptake and Endothelium-Dependent Vasodilation in Humans , 2003, Circulation.
[21] A. Schmidt,et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.
[22] E. Diamanti-Kandarakis,et al. Increased levels of serum advanced glycation end‐products in women with polycystic ovary syndrome , 2005, Clinical endocrinology.
[23] T. Hughes,et al. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. , 2004, Diabetes.
[24] R. Bucala,et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.
[25] H. Yamamoto,et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. , 2000, The Journal of biological chemistry.
[26] 堀江 勝智. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions : implication for glycoxidative stress in the pathogenesis of diabetic nephropathy , 1998 .
[27] L. Kuo,et al. TNF-&agr; Contributes to Endothelial Dysfunction in Ischemia/Reperfusion Injury , 2005 .
[28] Peter Libby,et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.
[29] K. Tracey,et al. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.
[30] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[31] R. Hofer-Warbinek,et al. The Transcription Factor NF-κB and the Regulation of Vascular Cell Function , 2000 .